Introduction
The diabetes epidemic has contributed to the expansion of the antidiabetics market in the past few years, and with prevalence increasing, this trend is set to continue. However, the highest selling drug classes in the market (sulfonylureas and biguanides) are now heavily genericized and will not generate the revenues required to drive this growth.
Scope of this report
- Country specific event-driven sales forecasts for 2005-14 for the US, Japan, France, Germany, Italy, Spain and the UK, plus a Global overview
- Patient potential and prescribing trends overview of the antidiabetics market based on historical sales data and future key events
- Examines the country and market specific issues which will impact future antidiabetic sales, including generic erosion and class switching
- Case studies demonstrating how Sanofi-Aventis built a strong insulin portfolio, and how BMS managed the Glucophage lifecycle
Research and analysis highlights
The insulin class continues to dominate the antidiabetics market, with a 37.5% share of its global sales. However, it is interesting to note that this class did not generate the greatest growth in the market. The thiazolidinediones experienced a superior growth in sales, while also accounting for the second largest portion of the market share.
In order for a company to achieve and maintain growth in this sector, the correct strategy needs to be followed. Novo Nordisk and Eli Lilly, the companies with the strongest presence in the insulin market, and Sanofi-Aventis, which is a relative newcomer, appear to follow the strategy of developing "insulin families" rather than isolated products.
Inhaled insulins are expected to play an important role in expanding the insulin market. However, whether they realize their full potential will depend on whether they deliver their promise of increased convenience and compliance.
Key reasons to read this report
- View independent, event-driven forecasts for key antidiabetic products and classes across the seven major markets
- Quantify the impact that the launch of novel antidiabetics will have to the market. Which established classes will be most severely affected?
- Identify the best strategy to build, launch and market a successful insulin portfolio. Compare the strategies followed by major companies
ABOUT DATAMONITOR HEALTHCARE
- About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the antidiabetics market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current market situation
- National markets
- The insulin market
- Humalog
- NovoLin
- Lantus
- Humulin
- NovoRapid/NovoLog
- Outlook
- Thiazolidinediones
- Actos
- Avandia
- Sulfonylureas
- Amaryl
- Glucotrol XL
- Biguanides
- Glucophage
- Strategic scoping and focus
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antidiabetics market
- Global opportunities and threats
- Opportunities
- Threats
- US: current market assessment
- Overview
- US market issues
- Japan: current market assessment
- Overview
- Japan market issues
- Europe: current market assessment
- Overview
- Europe market issues
- Summary of environmental issues affecting the antidiabetic market size
CHAPTER 4 FORECAST ANALYSIS
Assumptions and events
- Ongoing trends
- Increasing market size
- Trial results
- PROACTIVE
- CHICAGO and PERISCOPE
- DREAM
- ACCORD
- ADOPT
- ORIGIN
- NAVIGATOR
- New product launches
- Byetta and Exenatide LAR
- Symlin
- Pargluva
- Vildagliptin
- Liraglutide
- Exubera
- AERx iDMS
- Patent expiries
- Limitations of data
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Introduction
- Case study 1
- Aventis: Building a successful insulin portfolio
- Competitive landscape
- Lantus
- Lantus strategic analysis
- Conclusion
- Apidra
- Exubera
- The basis of commercial success
- Case study 2
- BMS: Managing the lifecycle of Glucophage
- Patent protection strategies
- DepoMed announces lawsuit against BMS for Glucophage XR patent infringement
- Study published in JAMA reveals Glucophage is prescribed to patients with heart and kidney disorders, despite black box warning of lactic acidosis side-effect
- Merck Sante announces a trademark and patent-licensing agreement with Sumitomo Pharmaceuticals for the development and commercialization of Glucophage and Glucophage XR in Japan
- BMS announces FDA approval of 750mg dose of Glucophage XR
- Strategic analysis
APPENDIX A - MAJOR BRAND KEY FACTS
- Insulin market data
- Humulin
- Humalog
- NovoLin
- NovoRapid/NovoLog
- Lantus
- TZDs market data
- Actos
- Avandia
- Sulfonylureas market data
- Amaryl
- Glucotrol XL
- Biguanide market data
- Glucophage and Glucophage XR
APPENDIX B
- Bibliography
- Epidemiology
- Clinical trial data
- Report methodology
- Standard units
- Japanese market data
- About Datamonitor
- About Datamonitor Healthcare
- About the Cardiovascular Disease analysis team
- Disclaimer
List of Tables
- Table 1: Global sales in the antidiabetic market by drug class, 2004
- Table 2: Global sales of the leading branded insulin families, 2003-04
- Table 3: Global sales of the leading branded TZDs, 2003-04
- Table 4: Global sales of the leading branded sulfonylureas, 2003-04
- Table 5: Global sales of the leading branded biguanide compared to generics, 2003-04
- Table 6: Future prevalence of type 1 and type 2 diabetes in the seven major markets, 2004-12
- Table 7: Prevalence of obesity in the seven major markets by age (000s), 2003
- Table 8: US sales and growth of drug classes
- Table 9: Japan sales and growth of drug classes
- Table 10: EU5 sales and growth of drug classes
- Table 11: Patent expiry dates used in forecasting antidiabetics market
- Table 12: Key Lantus events
- Table 13: Key Glucophage and Glucophage XR events
- Table 14: Annual cost of therapy for Glucophage brands versus generics
- Table 15: Humulin: key facts
- Table 16: Humalog: key facts
- Table 17: NovoLin: key facts
- Table 18: NovoLog: key facts
- Table 19: Lantus: key facts
- Table 20: Actos: key facts
- Table 21: Avandia: key facts
- Table 22: Amaryl: key facts
- Table 23: Glucotrol XL: key facts
- Table 24: Glucophage and Glucophage XR: key facts
List of Figures
- Figure 1: Sales and growth for antidiabetic drug classes in the seven major markets, 2003-04
- Figure 2: Share of antidiabetics market represented by each of the seven major markets in 2004
- Figure 3: Pioglitazones effects on triglyceride and HDL cholesterol levels
- Figure 4: Proportion of population 20-39 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
- Figure 5: Proportion of population 40-59 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
- Figure 6: Proportion of population 60-79 years of age, 2003 and 2015 and prevalence of diabetes in this age group, 2003
- Figure 7: Annual US sales of the antidiabetic drug classes, 2001-04
- Figure 8: Annual Japan sales of the antidiabetic drug classes, 2001-04
- Figure 9: Annual EU5 sales of the antidiabetic drug classes, 2001-04
- Figure 10: Summary of environmental issues
- Figure 11: SWOT analysis for Lantus
- Figure 12: SWOT analysis for the Glucophage franchise
